NASDAQ:MYNZ

Mainz Biomed B.V.


Mainz Biomed BV is engaged in developing molecular genetic diagnostic solutions for life-threatening conditions. It’s main product Coloalert is a kit that includes a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results.

In The Press

Mainz Biomed B.V. News

Jun 28, 2022

Mainz Biomed Enrolls First Patient in ColoFuture Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert

Read More
Jun 14, 2022

FDA approval could spark huge interest in Mainz Biomed (NASDAQ:MYNZ)

Read More
Jun 14, 2022

Mainz Biomed Appoints Vice President of Clinical Affairs to Lead US Clinical Studies in Support of FDA Submission

Read More
Jun 01, 2022

Mainz Biomed Successfully Completes Conformity Assessment to IVDR Achieving New Level of EU Regulatory Compliance

Read More
May 19, 2022

Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)

Read More
May 17, 2022

Mainz Biomed to Participate in H.C. Wainwright Global Investment Conference and Equity Forum German Spring Conference

Read More
May 09, 2022

Mainz Biomed to Host Key Opinion Leader Event at DDW 2022

Read More
May 05, 2022

Mainz Biomed Provides Product Development Update on PancAlert

Read More